secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001193125-24-164550
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Director Horobin resigns; shareholders approve plan amendment to include pre-funded warrants in evergreen
--------------------------------------------------------------------------------

- Director Joanna Horobin resigned from board and all committees on June 18, 2024; resignation not due to any disagreement.
- Jeffrey Albers appointed to Audit Committee; committee now consists of Ridloff, Esposito, Albers.
- Shareholders approved Amendment No. 1 to 2020 Stock Option Plan: 'Outstanding Shares' includes pre-funded warrants for annual evergreen increase.
- Shareholders elected Class I directors (Esposito, Hrustanovic, Sandor) and ratified Ernst & Young as independent auditor for FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312524164550/0001193125-24-164550-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312524164550/d841500d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-164550

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer